Cencora (COR) has attracted fresh attention after agreeing to support distribution of Kite’s FDA approved CAR T cell therapies, while also planning a CFO transition to Eva C. Boratto in June 2026. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results